{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:13Z","timestamp":1792895593189,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>More evidence-based strategies are needed for preventing and managing cancer treatment-related cardiovascular toxicity (CTR-CVT). Owing to the growing body of evidence supporting their cardioprotective role in several cardiac injury scenarios, sodium-glucose cotransporter 2 inhibitors (SGLT2i) may be beneficial for preventing and treating CTR-CVT. In October 2024, a search was conducted of the PubMed database to review full studies investigating the cardioprotective role of SGLT2i against CTR-CVT. We identified 44 full published\/pre-print studies and 3 ongoing randomised controlled trial across eight types of cancer treatment (anthracyclines, platinum-containing therapy, immune checkpoint inhibitors, HER2-targeted therapies, kinase inhibitors, androgen deprivation\u00a0therapies, multiple myeloma therapies and 5-fluorouracil). Most studies used animal models and focussed on primary prevention. 43 of the 44 studies found some cardioprotective effect of SGLT2i against CTR-CVT, which in some cases included preventing ejection fraction decline and aberrations in cardiac electrophysiological parameters. Some studies also observed beneficial effects on mortality. A central triad of anti-inflammatory, anti-oxidative and anti-apoptotic mechanisms likely underlie SGLT2i-mediated cardioprotection against CTR-CVT. Overall, this growing body of research suggests that SGLT2i may be a promising candidate for preventing CTR-CVT either as monotherapy or in combination with other cardioprotective drugs. However, the literature is limited in that no prospective randomised controlled trials investigating SGLT2i for the prevention and management of CTR-CVT exist and most existing human retrospective data is based on diabetic populations. Future work must focus on addressing these limitations of the current literature.<\/jats:p>","DOI":"10.1186\/s40959-024-00284-4","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:08:13Z","timestamp":1739286493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights"],"prefix":"10.1186","volume":"11","author":[{"given":"Carl","family":"Simela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Malcolm","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"4","key":"284_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"C Fitzmaurice","year":"2015","unstructured":"Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505\u201327.","journal-title":"JAMA Oncol"},{"issue":"9","key":"284_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547\u201358.","journal-title":"Nat Rev Cardiol"},{"key":"284_CR3","doi-asserted-by":"crossref","unstructured":"Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for Cardioprotection. Front Cardiovasc Med. 2022;9:847012.","DOI":"10.3389\/fcvm.2022.847012"},{"issue":"31","key":"284_CR4","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820\u20136.","journal-title":"J Clin Oncol"},{"issue":"10","key":"284_CR5","first-page":"4585","volume":"32","author":"M Montserrat","year":"2012","unstructured":"Montserrat M, Leveque D, Barthelemy P, Bergerat JP. Duration of adjuvant trastuzumab treatment in routine practice. Anticancer Res. 2012;32(10):4585\u20138.","journal-title":"Anticancer Res"},{"key":"284_CR6","doi-asserted-by":"crossref","unstructured":"Antunes P, Joaquim A, Sampaio F, Nunes C, Ascens\u00e3o A, Vilela E, et al. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial. European Journal of Preventive Cardiology. 2023.","DOI":"10.1093\/eurjpc\/zwad063"},{"issue":"3","key":"284_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/eurjpc\/zwab006","volume":"29","author":"J Murray","year":"2022","unstructured":"Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review. Eur J Prev Cardiol. 2022;29(3):463\u201372.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"284_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000529205","volume":"46","author":"N Zoth","year":"2023","unstructured":"Zoth N, Tomanek A, Seuthe K, Pfister R, Baumann FT. Exercise as Medicine Could Be a Chance for Early Detection and Prevention of Cardiotoxicity in Cancer Treatments: A Narrative Review. Oncology Research and Treatment. 2023;46(4):131\u20139.","journal-title":"Oncology Research and Treatment"},{"issue":"13","key":"284_CR9","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900\u20139.","journal-title":"Eur J Cancer"},{"issue":"2","key":"284_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","volume":"16","author":"F Caspani","year":"2021","unstructured":"Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(2):477\u201386.","journal-title":"Intern Emerg Med"},{"key":"284_CR11","doi-asserted-by":"crossref","unstructured":"Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity. JACC: CardioOncology. 2022;4(1):19\u201337.","DOI":"10.1016\/j.jaccao.2022.01.101"},{"key":"284_CR12","unstructured":"Cardiology ACo. STOP-CA Trial: Statin Therapy Associated With Reduced Heart Dysfunction From Anthracyclines 2023 [Available from: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2023\/03\/01\/22\/45\/sat-930am-stop-ca-acc-2023."},{"issue":"1","key":"284_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs"},{"issue":"16","key":"284_CR14","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"21","key":"284_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"284_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"12","key":"284_CR17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"284_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","volume":"167","author":"JRB Dyck","year":"2022","unstructured":"Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, Zuurbier CJ. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17\u201331.","journal-title":"J Mol Cell Cardiol"},{"issue":"41","key":"284_CR19","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361","journal-title":"Eur Heart J"},{"key":"284_CR20","unstructured":"Rohatgi A. WebPlotDigitizer 2022 [Available from: https:\/\/automeris.io\/WebPlotDigitizer]."},{"key":"284_CR21","doi-asserted-by":"crossref","unstructured":"Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985\u20132010. JAMA Network Open. 2023;6(2):e2254669-e.","DOI":"10.1001\/jamanetworkopen.2022.54669"},{"issue":"1","key":"284_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40959-020-00079-3","volume":"6","author":"JAM Kamphuis","year":"2020","unstructured":"Kamphuis JAM, Linschoten M, Cramer MJ, Doevendans PA, Asselbergs FW, Teske AJ. Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy. Cardio-Oncology. 2020;6(1):23.","journal-title":"Cardio-Oncology"},{"issue":"1","key":"284_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63\u201375.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"284_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3892\/mmr.2021.12342","volume":"24","author":"H Shi","year":"2021","unstructured":"Shi H, Zeng Q, Wei Y, Yang H, Tang H, Wang D, et al. Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin-induced cardiotoxicity in rats. Mol Med Rep. 2021;24(4):703.","journal-title":"Mol Med Rep"},{"key":"284_CR25","doi-asserted-by":"crossref","unstructured":"van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines.\u00a0Cochrane Database Syst Rev. 2011;(6).","DOI":"10.1002\/14651858.CD003917.pub4"},{"issue":"11","key":"284_CR26","first-page":"6063","volume":"37","author":"H Mizutani","year":"2017","unstructured":"Mizutani H, Hotta S, Nishimoto A, Ikemura K, Miyazawa D, Ikeda Y, et al. Pirarubicin, an Anthracycline Anticancer Agent, Induces Apoptosis Through Generation of Hydrogen Peroxide. Anticancer Res. 2017;37(11):6063\u20139.","journal-title":"Anticancer Res"},{"key":"284_CR27","doi-asserted-by":"crossref","unstructured":"Shi H, Tang H, Ai W, Zeng Q, Yang H, Zhu F, et al. Schisandrin B antagonizes cardiotoxicity induced by pirarubicin by inhibiting Mitochondrial Permeability Transition Pore (mPTP) opening and decreasing cardiomyocyte apoptosis.\u00a0Front Pharmacol. 2021;12:733805.","DOI":"10.3389\/fphar.2021.733805"},{"issue":"1","key":"284_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3892\/etm.2021.10991","volume":"23","author":"H Tang","year":"2022","unstructured":"Tang H, Zhao J, Feng R, Pu P, Wen L. Reducing oxidative stress may be important for treating pirarubicin-induced cardiotoxicity with schisandrin B. Exp Ther Med. 2022;23(1):68.","journal-title":"Exp Ther Med"},{"key":"284_CR29","doi-asserted-by":"crossref","unstructured":"Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S. SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: A systematic-review and meta-analysis. Vascular Pharmacology. 2023:107171.","DOI":"10.1016\/j.vph.2023.107171"},{"issue":"9","key":"284_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12012-021-09665-y","volume":"21","author":"V Bar\u0131\u015f","year":"2021","unstructured":"Bar\u0131\u015f V, Din\u00e7soy AB, Gedikli E, Z\u0131rh S, M\u00fcft\u00fco\u011flu S, Erdem A. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways. Cardiovasc Toxicol. 2021;21(9):747\u201358.","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"284_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","volume":"95","author":"WT Chang","year":"2021","unstructured":"Chang WT, Lin YW, Ho CH, Chen ZC, Liu PY, Shih JY. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. Arch Toxicol. 2021;95(2):659\u201371.","journal-title":"Arch Toxicol"},{"issue":"7","key":"284_CR32","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","volume":"96","author":"WT Chang","year":"2022","unstructured":"Chang WT, Shih JY, Lin YW, Chen ZC, Kan WC, Lin TH, Hong CS. Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Arch Toxicol. 2022;96(7):2021\u201332.","journal-title":"Arch Toxicol"},{"issue":"17","key":"284_CR33","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.3390\/ijms231710146","volume":"23","author":"PL Hsieh","year":"2022","unstructured":"Hsieh PL, Chu PM, Cheng HC, Huang YT, Chou WC, Tsai KL, et al. Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating AKT-mediated oxidative stress, cardiac remodeling, and inflammation. Int J Mol Sci. 2022;23(17):10146.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"284_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1):150.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"284_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","volume":"19","author":"J Sabatino","year":"2020","unstructured":"Sabatino J, De Rosa S, Tamm\u00e8 L, Iaconetti C, Sorrentino S, Polimeni A, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"284_CR36","first-page":"369","volume":"9","author":"CY Wang","year":"2020","unstructured":"Wang CY, Chen CC, Lin MH, Su HT, Ho MY, Yeh JK, et al. TLR9 Binding to Beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity. Biology (Basel). 2020;9(11):369.","journal-title":"Biology (Basel)"},{"issue":"10","key":"284_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiology. 2019;4(10):1007\u201318.","journal-title":"JAMA Cardiology"},{"key":"284_CR38","doi-asserted-by":"crossref","unstructured":"Dobson R, Ghosh AK, Ky B, Marwick T, Stout M, Harkness A, et al. BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and\/or Trastuzumab. JACC: CardioOncology. 2021;3(1):1\u201316.","DOI":"10.1016\/j.jaccao.2021.01.011"},{"issue":"1","key":"284_CR39","first-page":"58","volume":"10","author":"AJ Daniele","year":"2024","unstructured":"Daniele AJ, Gregorietti V, Costa D, L\u00f3pez-Fern\u00e1ndez T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial. Cardiooncology. 2024;10(1):58.","journal-title":"Cardiooncology"},{"issue":"11","key":"284_CR40","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"key":"284_CR41","doi-asserted-by":"crossref","unstructured":"Agarwal S, Qamar U, Fujiwara Y, Guha A, Naqash AR, Yang EH, et al. The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Patients With Cancer: A Systematic Review and Meta-Analysis. The American Journal of Cardiology. 2024.","DOI":"10.1016\/j.amjcard.2024.01.032"},{"key":"284_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.amjcard.2024.04.032","volume":"222","author":"AR Fath","year":"2024","unstructured":"Fath AR, Aglan M, Aglan A, Chilton RJ, Trakhtenbroit A, Al-Shammary OA, et al. Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study. Am J Cardiol. 2024;222:175\u201382.","journal-title":"Am J Cardiol"},{"issue":"3","key":"284_CR43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","volume":"5","author":"H Abdel-Qadir","year":"2023","unstructured":"Abdel-Qadir H, Carrasco R, Austin PC, Chen Y, Zhou L, Fang J, et al. The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer. JACC CardioOncol. 2023;5(3):318\u201328.","journal-title":"JACC CardioOncol"},{"key":"284_CR44","doi-asserted-by":"crossref","unstructured":"Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, et al. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. JACC Heart Fail. 2022;10(8):559\u201367.>","DOI":"10.1016\/j.jchf.2022.03.006"},{"key":"284_CR45","doi-asserted-by":"publisher","unstructured":"Chiang C-H, Chiang C-H, Chiang C-H, Ma KS-K, Peng C-Y, Hsia YP, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023 2023\/02\/\/; 109(6):[470\u20137 pp.]. Available from: http:\/\/europepmc.org\/abstract\/MED\/36351793https:\/\/doi.org\/10.1136\/heartjnl-2022-321545.","DOI":"10.1136\/heartjnl-2022-321545"},{"key":"284_CR46","doi-asserted-by":"crossref","unstructured":"Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, et al. SGLT2 Inhibitor Use and Risk of Clinical\u00a0Events in Patients With Cancer Therapy\u2013Related Cardiac Dysfunction. JACC: Heart Failure. 2024;12(1):67\u201378.","DOI":"10.1016\/j.jchf.2023.08.026"},{"key":"284_CR47","doi-asserted-by":"publisher","first-page":"1250185","DOI":"10.3389\/fcvm.2023.1250185","volume":"10","author":"F Giangiacomi","year":"2023","unstructured":"Giangiacomi F, Faggiano A, Cardinale D, Rossi FG, Pollina A, Gherbesi E, et al. Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction-a case series. Front Cardiovasc Med. 2023;10:1250185.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"284_CR48","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s12872-024-04189-z","volume":"24","author":"H Oda","year":"2024","unstructured":"Oda H, Hayashi Y, Oyanagi N, Tanaka K, Ozaki K, Kashiwa A, et al. Add-on multidrug treatment based on quadruple therapy successfully treated worsening heart failure caused by anthracycline-induced cardiomyopathy in a survivor of cancer as a young adult: a case report. BMC Cardiovasc Disord. 2024;24(1):505.","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"284_CR49","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/pharmaceutics14122629","volume":"14","author":"D Kim","year":"2022","unstructured":"Kim D, Jang G, Hwang J, Wei X, Kim H, Son J, et al. Combined therapy of low-dose angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitor prevents doxorubicin-induced cardiac dysfunction in rodent model with minimal adverse effects. Pharmaceutics. 2022;14(12):2629.","journal-title":"Pharmaceutics"},{"issue":"12","key":"284_CR50","first-page":"4403","volume":"26","author":"E Belen","year":"2022","unstructured":"Belen E, Canbolat IP, Yigitt\u00fcrk G, Cetinarslan \u00d6, Akdeniz CS, Karaca M, et al. Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats. Eur Rev Med Pharmacol Sci. 2022;26(12):4403\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"284_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxres\/tfad007","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis. Toxicol Res (Camb). 2023;12(2):216\u201323.","journal-title":"Toxicol Res (Camb)"},{"key":"284_CR52","doi-asserted-by":"crossref","unstructured":"Hu J, Xu J, Tan X, Li D, Yao D, Xu B, Lei Y. Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn Schmiedebergs Arch Pharmacol. 2023.","DOI":"10.1007\/s00210-023-02409-5"},{"issue":"2","key":"284_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12012-023-09784-8","volume":"23","author":"SM Satyam","year":"2023","unstructured":"Satyam SM, Bairy LK, Shetty P, Sainath P, Bharati S, Ahmed AZ, et al. Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach. Cardiovasc Toxicol. 2023;23(2):107\u201319.","journal-title":"Cardiovasc Toxicol"},{"key":"284_CR54","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","volume":"109","author":"CC Yang","year":"2019","unstructured":"Yang CC, Chen YT, Wallace CG, Chen KH, Cheng BC, Sung PH, et al. Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomed Pharmacother. 2019;109:658\u201370.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"284_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.14744\/AnatolJCardiol.2023.2825","volume":"27","author":"S Ulusan","year":"2023","unstructured":"Ulusan S, G\u00fclle K, Peynirci A, Sevimli M, Karaibrahimoglu A, Kuyumcu MS. Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity. Anatol J Cardiol. 2023;27(6):339\u201347.","journal-title":"Anatol J Cardiol"},{"key":"284_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131331","volume":"391","author":"A Avagimyan","year":"2023","unstructured":"Avagimyan A, Sheibani M, Pogosova N, Mkrtchyan L, Yeranosyan H, Aznauryan A, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391: 131331.","journal-title":"Int J Cardiol"},{"key":"284_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2024.114863","volume":"191","author":"WSM El-Sawy","year":"2024","unstructured":"El-Sawy WSM, El-Bahrawy AH, Messiha BAS, Hemeida RAM, Khalaf MM. The impact of PPAR-\u03b3\/Nrf-2\/HO-1, NF-\u03baB\/IL-6\/ Keap-1, and Bcl-2\/caspase-3\/ATG-5 pathways in mitigation of DOX-induced cardiotoxicity in an animal model: The potential cardioprotective role of oxyresveratrol and\/or dapagliflozin. Food Chem Toxicol. 2024;191: 114863.","journal-title":"Food Chem Toxicol"},{"issue":"5","key":"284_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3892\/mmr.2024.13198","volume":"29","author":"A Malik","year":"2024","unstructured":"Malik A, Bagchi AK, Jassal DS, Singal PK. Doxorubicin-induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways. Mol Med Rep. 2024;29(5):74.","journal-title":"Mol Med Rep"},{"key":"284_CR59","doi-asserted-by":"publisher","first-page":"1289663","DOI":"10.3389\/fcvm.2024.1289663","volume":"11","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello V, Canale ML, Bisceglia I, Iovine M, Paccone A, Maurea C, et al. Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-\u03baB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. Front Cardiovasc Med. 2024;11:1289663.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"284_CR60","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","volume":"49","author":"CM Oh","year":"2019","unstructured":"Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, et al. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure. Korean Circ J. 2019;49(12):1183\u201395.","journal-title":"Korean Circ J"},{"key":"284_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116759","volume":"176","author":"HY Chang","year":"2024","unstructured":"Chang HY, Hsu HC, Fang YH, Liu PY, Liu YW. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway. Biomed Pharmacother. 2024;176: 116759.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"284_CR62","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s11010-023-04830-z","volume":"479","author":"R Lin","year":"2024","unstructured":"Lin R, Peng X, Li Y, Wang X, Liu X, Jia X, et al. Empagliflozin attenuates doxorubicin-impaired cardiac contractility by suppressing reactive oxygen species in isolated myocytes. Mol Cell Biochem. 2024;479(8):2105\u201318.","journal-title":"Mol Cell Biochem"},{"key":"284_CR63","doi-asserted-by":"crossref","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Botti G, Maurea N. SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, Leukotrienes\/Interleukin 6 axis and mTORC1 \/Fox01\/3a mediated apoptosis. European Heart Journal. 2020;41(Supplement_2).","DOI":"10.1093\/ehjci\/ehaa946.3253"},{"issue":"1","key":"284_CR64","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7326\/0003-4819-105-1-48","volume":"105","author":"DC Doll","year":"1986","unstructured":"Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48\u201351.","journal-title":"Ann Intern Med"},{"issue":"3","key":"284_CR65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jaccao.2020.06.004","volume":"2","author":"AC Cameron","year":"2020","unstructured":"Cameron AC, McMahon K, Hall M, Neves KB, Rios FJ, Montezano AC, et al. Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer. JACC CardioOncol. 2020;2(3):443\u201355.","journal-title":"JACC CardioOncol"},{"key":"284_CR66","doi-asserted-by":"crossref","unstructured":"El-Awady E-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. European Journal of Pharmacology. 2011;650(1):335\u201341.","DOI":"10.1016\/j.ejphar.2010.09.085"},{"key":"284_CR67","doi-asserted-by":"crossref","unstructured":"Ali FEM, Hassanein EHM, Abd El-Ghafar OAM, Rashwan EK, Saleh FM, Atwa AM. Exploring the cardioprotective effects of canagliflozin against cisplatin-induced cardiotoxicity: Role of iNOS\/NF-\u03baB, Nrf2, and Bax\/cytochrome C\/Bcl-2 signals. J Biochem Mol Toxicol. 2023:e23309.","DOI":"10.1002\/jbt.23309"},{"issue":"3","key":"284_CR68","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/rej.2010.1141","volume":"14","author":"P Ferroni","year":"2011","unstructured":"Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P, et al. Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuvenation Res. 2011;14(3):293\u2013308.","journal-title":"Rejuvenation Res"},{"issue":"5","key":"284_CR69","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"9","key":"284_CR70","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"284_CR71","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"20","key":"284_CR72","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/cancers13205218","volume":"13","author":"W Shalata","year":"2021","unstructured":"Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel). 2021;13(20):5218.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"284_CR73","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.3390\/ijms21207802","volume":"21","author":"V Quagliariello","year":"2020","unstructured":"Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A, et al. NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. Int J Mol Sci. 2020;21(20):7802.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"284_CR74","first-page":"2","volume":"10","author":"MG Perelman","year":"2024","unstructured":"Perelman MG, Brzezinski RY, Waissengrin B, Leshem Y, Bainhoren O, Rubinstein TA, et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardiooncology. 2024;10(1):2.","journal-title":"Cardiooncology"},{"issue":"8","key":"284_CR75","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","volume":"116","author":"K Lemmens","year":"2007","unstructured":"Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116(8):954\u201360.","journal-title":"Circulation"},{"issue":"5","key":"284_CR76","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"284_CR77","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019;34(4):451\u20138.","journal-title":"Curr Opin Cardiol"},{"key":"284_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121207","volume":"312","author":"J Min","year":"2023","unstructured":"Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, et al. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci. 2023;312: 121207.","journal-title":"Life Sci"},{"issue":"2","key":"284_CR79","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/antiox12020457","volume":"12","author":"G M\u00e9ndez-Vald\u00e9s","year":"2023","unstructured":"M\u00e9ndez-Vald\u00e9s G, G\u00f3mez-Hevia F, Bragato MC, Lillo-Moya J, Rojas-Sol\u00e9 C, Saso L, et al. Antioxidant protection against Trastuzumab cardiotoxicity in breast cancer therapy. Antioxidants (Basel). 2023;12(2):457.","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"284_CR80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48.","journal-title":"Mol Cancer"},{"key":"284_CR81","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3389\/fphar.2020.00891","volume":"11","author":"Y Jin","year":"2020","unstructured":"Jin Y, Xu Z, Yan H, He Q, Yang X, Luo P. A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors. Front Pharmacol. 2020;11:891.","journal-title":"Front Pharmacol"},{"key":"284_CR82","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/OTT.S170138","volume":"11","author":"M Chaar","year":"2018","unstructured":"Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther. 2018;11:6227\u201337.","journal-title":"Onco Targets Ther"},{"key":"284_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2021.106949","volume":"142","author":"R Madonna","year":"2022","unstructured":"Madonna R, Barachini S, Moscato S, Ippolito C, Mattii L, Lenzi C, et al. Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy. Vascul Pharmacol. 2022;142: 106949.","journal-title":"Vascul Pharmacol"},{"key":"284_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.664181","volume":"12","author":"C Ren","year":"2021","unstructured":"Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J, et al. Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy. Front Pharmacol. 2021;12: 664181.","journal-title":"Front Pharmacol"},{"key":"284_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117278","volume":"178","author":"L Mattii","year":"2024","unstructured":"Mattii L, Moscato S, Ippolito C, Polizzi E, Novo G, Zucchi R, et al. Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway. Biomed Pharmacother. 2024;178: 117278.","journal-title":"Biomed Pharmacother"},{"key":"284_CR86","doi-asserted-by":"crossref","unstructured":"Liu CH, Ho YC, Lee WC, Huang CY, Lee YK, Hsieh CB, et al. Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin Attenuates Sorafenib-Induced Myocardial Inflammation and Toxicity. Environ Toxicol. 2024.","DOI":"10.1002\/tox.24362"},{"issue":"9","key":"284_CR87","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41569-018-0030-z","volume":"15","author":"Z Ungvari","year":"2018","unstructured":"Ungvari Z, Tarantini S, Kiss T, Wren JD, Giles CB, Griffin CT, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. Nat Rev Cardiol. 2018;15(9):555\u201365.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"284_CR88","first-page":"291","volume":"2014","author":"RJ Widmer","year":"2014","unstructured":"Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;2014(3):291\u2013308.","journal-title":"Glob Cardiol Sci Pract"},{"key":"284_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114907","volume":"164","author":"MS Dabour","year":"2023","unstructured":"Dabour MS, Abdelgawad IY, Grant MKO, El-Sawaf ES, Zordoky BN. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. Biomed Pharmacother. 2023;164: 114907.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"284_CR90","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/antiox13060671","volume":"13","author":"MY George","year":"2024","unstructured":"George MY, Dabour MS, Rashad E, Zordoky BN. Empagliflozin alleviates carfilzomib-induced cardiotoxicity in mice by modulating oxidative stress, inflammatory response, endoplasmic reticulum stress, and autophagy. Antioxidants (Basel). 2024;13(6):671.","journal-title":"Antioxidants (Basel)"},{"key":"284_CR91","doi-asserted-by":"publisher","first-page":"960327123119339","DOI":"10.1177\/09603271231193392","volume":"42","author":"MM Mahmoud Refaie","year":"2023","unstructured":"Mahmoud Refaie MM, Bayoumi AM, Mokhemer SA, Shehata S, Abd El-Hameed NM. Role of hypoxia inducible factor\/vascular endothelial growth factor\/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity. Hum Exp Toxicol. 2023;42:9603271231193392.","journal-title":"Hum Exp Toxicol"},{"key":"284_CR92","doi-asserted-by":"publisher","first-page":"175883591878014","DOI":"10.1177\/1758835918780140","volume":"10","author":"JD Sara","year":"2018","unstructured":"Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"284_CR93","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s43188-023-00204-1","volume":"40","author":"MMM Refaie","year":"2024","unstructured":"Refaie MMM, Shehata S, El-Hussieny M, Fawzy MA, Ahmed NZM, Marey H, et al. Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNF\u03b1\/TLR\/NF-\u03baB signaling pathway in rats. Toxicol Res. 2024;40(1):139\u201351.","journal-title":"Toxicol Res"},{"issue":"9","key":"284_CR94","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11912-023-01424-2","volume":"25","author":"J Kim","year":"2023","unstructured":"Kim J, Freeman K, Ayala A, Mullen M, Sun Z, Rhee J-W. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice. Curr Oncol Rep. 2023;25(9):965\u201377.","journal-title":"Curr Oncol Rep"},{"key":"284_CR95","doi-asserted-by":"crossref","unstructured":"Tang Z, Chang Y-C, Chi K-Y, Chang Y, Lee T-N, Hsiao C-L, et al. Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes of prostate cancer patients receiving gonadotropin-releasing hormone agonists. European Journal of Preventive Cardiology. 2024:zwae267.","DOI":"10.1093\/eurjpc\/zwae267"},{"issue":"7","key":"284_CR96","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","volume":"31","author":"H-D Zhang","year":"2024","unstructured":"Zhang H-D, Ding L, Mi L-J, Zhang A-K, Zhang K, Jiang Z-H, et al. Sodium\u2013glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol. 2024;31(7):770\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"284_CR97","doi-asserted-by":"publisher","first-page":"817","DOI":"10.32604\/or.2024.048988","volume":"32","author":"S Karim","year":"2024","unstructured":"Karim S, Alghanmi AN, Jamal M, Alkreathy H, Jamal A, Alkhatabi HA, et al. A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells. Oncol Res. 2024;32(5):817\u201330.","journal-title":"Oncol Res"},{"issue":"4","key":"284_CR98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jhbp.1391","volume":"31","author":"S Fujiyoshi","year":"2024","unstructured":"Fujiyoshi S, Honda S, Ara M, Kondo T, Kobayashi N, Taketomi A. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma. J Hepatobiliary Pancreat Sci. 2024;31(4):223\u201333.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"284_CR99","doi-asserted-by":"crossref","unstructured":"Karzoon A, Yerer MB, Cumao\u011flu A. Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects. Naunyn Schmiedebergs Arch Pharmacol. 2024.","DOI":"10.1007\/s00210-024-03316-z"},{"key":"284_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116140","volume":"223","author":"H Huang","year":"2024","unstructured":"Huang H, Kung FL, Huang YW, Hsu CC, Guh JH, Hsu LC. Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin. Biochem Pharmacol. 2024;223: 116140.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"284_CR101","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11154-021-09675-9","volume":"22","author":"KTK Lau","year":"2021","unstructured":"Lau KTK, Ng L, Wong JWH, Loong HHF, Chan WWL, Lee CH, Wong CKH. Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment \u2013 A Review. Rev Endocr Metab Disord. 2021;22(4):1121\u201336.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"284_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101500","volume":"50","author":"YM Huang","year":"2024","unstructured":"Huang YM, Chen WM, Jao AT, Chen M, Shia BC, Wu SY. Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes. Diabetes Metab. 2024;50(1): 101500.","journal-title":"Diabetes Metab"},{"key":"284_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106448","volume":"184","author":"R Marfella","year":"2022","unstructured":"Marfella R, Scisciola L, D\u2019Onofrio N, Maiello C, Trotta MC, Sardu C, et al. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res. 2022;184: 106448.","journal-title":"Pharmacol Res"},{"issue":"1","key":"284_CR104","doi-asserted-by":"publisher","first-page":"21756","DOI":"10.1038\/s41598-023-48678-1","volume":"13","author":"HJ Hwang","year":"2023","unstructured":"Hwang HJ, Kim M, Jun JE, Yon DK. Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea. Sci Rep. 2023;13(1):21756.","journal-title":"Sci Rep"},{"key":"284_CR105","doi-asserted-by":"crossref","unstructured":"Henson BD, Bale-Neary CA, Mecaskey R, Gbujie O, Zhan M, Rao K, Carbone S. SGLT2 Inhibitors, Malnutrition, Cachexia, and Survival in Heart Failure Patients with a History of Anthracycline Treatment. J Cardiovasc Pharmacol. 2024.","DOI":"10.1097\/FJC.0000000000001620"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00284-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-024-00284-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00284-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:37:44Z","timestamp":1739461064000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-024-00284-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1186\/s40959-024-00284-4","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}